Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Work
Year: 2015
Type: article
Abstract: Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irre... more
Source: New England Journal of Medicine
Institutions The Ohio State University, UC Irvine Health, University of California, Irvine, University of Oxford, King's College Hospital NHS Foundation Trust +11 more
Cites: 37
Cited by: 832
Related to: 10
FWCI: 50.71
Citation percentile (by year/subfield): 99.99
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze